Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:GBIO), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Fintel reports that on August 13, 2025, Wedbush downgraded their outlook for Generation Bio (NasdaqGS:GBIO) from Outperform to Neutral. Analyst Price Forecast Suggests 985.09% Upside As of August 6, ...

Wedbush analyst David Nierengarten on Wednesday downgraded Generation Bio (GBIO) to ‘Neutral’ from ‘Outperform’ with a $7 price target after the company announced a strategic restructuring. Shares of ...

Generation Bio (GBIO) presented data on its cell-targeted lipid nanoparticle – ctLNP – and immune-quiet DNA – iqDNA – platforms at the European Society of Gene and Cell Therapy 31st Annual Congress.

Generation Bio is a biotechnology company aiming to treat autoimmune disorders by delivering gene-silencing molecules to T cells, a specific type of immune cell. Its platform centers on a proprietary ...

XOMA Royalty (XOMA) has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share. Generation Bio stockholders also will receive one non-transferable contingent ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generation Bio, which once ...